OncLive® On Air

S13 Ep24: Biomarker-Directed Therapies Improve Outlooks for the mCRC Treatment Arsenal: With Chandler Park, MD; and Midhun Malla, MD


Listen Later

In this episode of MedNews Week's Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was rejoined by Midhun Malla, MD, of the University of Alabama at Birmingham, to discuss therapeutic options for patients with metastatic colorectal cancer (mCRC), particularly in the third-line setting and beyond.

In the final part of this 3-part episode miniseries, Drs Park and Malla explored the challenges faced by community oncologists, especially in rural or underserved areas, in accessing clinical trials, which remain a preferred disease management approach due to their role in advancing novel therapies. However, in the absence of trial availability or when patients are ineligible, they emphasized the importance of evidence-based, FDA-approved agents for later lines of therapy.

Three primary agents were discussed for patients who have progressed on first-line FOLFOX (folinic acid, fluorouracil, and oxaliplatin) and second-line FOLFIRI (folinic acid, fluorouracil, and irinotecan) regimens: trifluridine/tipiracil (TAS-102; Lonsurf) plus bevacizumab (Avastin); fruquintinib (Fruzaqla); and regorafenib (Stivarga). These agents offer viable treatment pathways in biomarker-unselected patient populations. However, direct comparisons between these agents are lacking, as most were tested against placebo controls. The choice among them is often individualized based on patient performance status, prior exposure to biologics, and toxicity profiles.

TAS-102 plus bevacizumab has generated promising results, though real-world data may show diminished efficacy due to frequent prior exposure to 5-fluorouracil and bevacizumab in US patients. Fruquintinib offers a VEGF-targeted approach with a more favorable hematologic toxicity profile, whereas regorafenib is associated with notable adverse effects, including hypertension, gastrointestinal toxicity, and mucositis. Park and Malla emphasized the importance of treatment sequencing, toxicity management, and individualized patient-centered care, including consideration of dose modifications to preserve quality of life in later-line settings.

In addition to later-line options, the conversation also touched on emerging frontline therapies. Notable investigational agents include zanidatimab-hrii (Ziihera) and KRAS G12C–directed therapies. Additionally, a novel integrin-targeted cytotoxin is currently under evaluation at the University of Alabama at Birmingham in patients with treatment-naive mCRC. This agent induces apoptosis via caspase-8 activation and has demonstrated encouraging preclinical activity. Overall, the discussion highlighted a nuanced, biomarker-informed, and patient-tailored approach to mCRC management, emphasizing both the value of clinical trials and the importance of optimizing currently available therapies.
...more
View all episodesView all episodes
Download on the App Store

OncLive® On AirBy OncLive® On Air

  • 4.2
  • 4.2
  • 4.2
  • 4.2
  • 4.2

4.2

21 ratings


More shows like OncLive® On Air

View all
Wait Wait... Don't Tell Me! by NPR

Wait Wait... Don't Tell Me!

38,689 Listeners

Marketplace Morning Report by Marketplace

Marketplace Morning Report

902 Listeners

Marketplace by Marketplace

Marketplace

8,659 Listeners

Research To Practice | Oncology Videos by Dr Neil Love

Research To Practice | Oncology Videos

113 Listeners

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast by PVI, PeerView Institute for Medical Education

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

10 Listeners

JAMA Clinical Reviews by JAMA Network

JAMA Clinical Reviews

493 Listeners

ASCO Daily News by American Society of Clinical Oncology (ASCO)

ASCO Daily News

58 Listeners

The Curbsiders Internal Medicine Podcast by The Curbsiders Internal Medicine Podcast

The Curbsiders Internal Medicine Podcast

3,332 Listeners

OncoPharm by John Bossaer

OncoPharm

185 Listeners

ASCO Guidelines by American Society of Clinical Oncology (ASCO)

ASCO Guidelines

43 Listeners

Lung Cancer Considered by IASLC

Lung Cancer Considered

27 Listeners

Oncology Today with Dr Neil Love by Dr. Neil Love

Oncology Today with Dr Neil Love

56 Listeners

Two Onc Docs by Sam and Karine

Two Onc Docs

169 Listeners

Oncology Brothers: Practice-Changing Cancer Discussions by Oncology Brothers

Oncology Brothers: Practice-Changing Cancer Discussions

39 Listeners

NEJM AI Grand Rounds by NEJM Group

NEJM AI Grand Rounds

54 Listeners